A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors
This study is testing a targeted radiation treatment called AlphaMedix for adults with neuroendocrine tumors, which are tumors that form in hormone-making cells. Researchers want to see how safe and effective this special treatment is for helping patients whose tumors have continued to grow.
Adults 18 and older with confirmed neuroendocrine tumors that cannot be surgically removed or have spread may qualify. Patients must have certain protein receptors on their tumors and have experienced disease growth despite previous treatments like somatostatin analogs.
Participants will receive the study treatment, which uses targeted radiation to home in on the tumor cells. Your health team will carefully monitor you throughout the study to check your safety and see how well the treatment works.
This study takes place at multiple locations, including sites in Colorado, Florida, and Louisiana. Currently, the study is active but not actively recruiting new participants.
- 1Tests a targeted radiation treatment called AlphaMedix for certain neuroendocrine tumors.
- 2Open to adults whose tumors have grown despite previous standard therapies.
- 3Currently active at multiple locations in the United States, though not currently taking new patients.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.